Legend Biotech CARVYKTI® Sales Hit $369M
Ticker: LEGN · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, pharmaceutical, collaboration
TL;DR
Legend Biotech's CARVYKTI® pulled in $369M last quarter, good news for the stock.
AI Summary
Legend Biotech Corporation announced on April 15, 2025, that its CARVYKTI® drug generated approximately $369 million in net trade sales for the quarter ended March 31, 2025. This figure is based on information provided by Janssen Biotech, Inc., its collaborator under a December 21, 2017 agreement.
Why It Matters
This preliminary sales figure for CARVYKTI® provides investors with an early look at the drug's commercial performance, impacting Legend Biotech's revenue expectations.
Risk Assessment
Risk Level: low — This is a routine sales update and does not introduce new material risks.
Key Numbers
- $369 million — CARVYKTI® Net Trade Sales (For the quarter ended March 31, 2025)
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (product) — Drug with reported sales
- Janssen Biotech, Inc. (company) — Collaborator providing sales data
- $369 million (dollar_amount) — Net trade sales for CARVYKTI®
- March 31, 2025 (date) — End of reporting quarter
- April 15, 2025 (date) — Date of announcement
- December 21, 2017 (date) — Date of collaboration agreement
FAQ
What is the total net trade sales for CARVYKTI® for the quarter ended March 31, 2025?
CARVYKTI® generated approximately $369 million in net trade sales for the quarter ended March 31, 2025.
Who provided the sales information to Legend Biotech?
The sales information was provided to Legend Biotech by Janssen Biotech, Inc.
When was the collaboration and license agreement between Legend Biotech and Janssen signed?
The collaboration and license agreement was dated as of December 21, 2017.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 15, 2025.
Does Legend Biotech file annual reports under Form 20-F or 40-F?
Legend Biotech indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding Legend Biotech Corp (LEGN).